Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi Year Shareholder Returns
Edgewise Therapeutics (EWTX) has seen strong long-term shareholder returns, up 111% in one year and 224% in three years, despite recent short-term dips. The company, which is developing therapies for muscle disorders and is currently loss-making, trades at a high price-to-book ratio of 6.9x, indicating a premium valuation based on future revenue potential rather than current financial performance. This valuation suggests high market expectations for its pipeline and clinical success, which could be sensitive to any disappointing news.
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
Edgewise Therapeutics, Inc. announced that its leadership will present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026, at 10:00 am ET. The company, a biopharmaceutical firm focused on muscle diseases, will provide a live webcast of the presentation. They are developing novel therapeutics for muscular dystrophies and serious cardiac conditions, including Sevasemten for Becker and Duchenne muscular dystrophies, and EDG-7500 and EDG-15400 for hypertrophic cardiomyopathy and heart failure, respectively.
Muscle disease drug developer heads to RBC healthcare event May 20
Edgewise Therapeutics (EWTX) announced its leadership will present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026, at 10:00 AM ET. The presentation will cover its drug pipeline, including Sevasemten for muscular dystrophies and EDG-7500 and EDG-15400 for cardiac conditions. Investors can access a live webcast and replay of the event.
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
Edgewise Therapeutics announced that its leadership will present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026, at 10:00 am ET. The presentation will be webcast live and accessible for replay. Edgewise Therapeutics is a biopharmaceutical company focused on developing novel treatments for muscular dystrophies and serious cardiac conditions, with several therapeutics currently in clinical trials.
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
Edgewise Therapeutics announced that its leadership will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 20, 2026, at 10:00 am ET. A live webcast of the presentation will be available on the company's website and accessible for replay. Edgewise Therapeutics is a biopharmaceutical company focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions.
Edgewise Therapeutics' Update for EDG-7500 Could Boost Shares, RBC Says
RBC Capital Markets highlighted that Edgewise Therapeutics' upcoming update for its lead drug candidate, EDG-7500, has the potential to significantly increase its stock value. The update focuses on the oral drug designed to treat hypertrophic cardiomyopathy, an orphan disease. Analysts are particularly interested in the details regarding the drug's efficacy and any additional clinical data.
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50
RBC Capital has reiterated its Buy rating on Edgewise Therapeutics (EWTX.US) and maintained its price target at $50. This suggests a continued positive outlook on the company's stock performance by the investment bank.
Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
Edgewise Therapeutics, Inc. announced its earnings results for the first quarter ended March 31, 2026, reporting a net loss of USD 49.01 million, which is an increase from a net loss of USD 40.8 million in the same period last year. The basic and diluted loss per share from continuing operations was USD 0.46, compared to USD 0.43 a year ago. The company's shares experienced a decline following these wider-than-expected Q1 losses.
Edgewise Therapeutics earnings on deck as losses widen
Edgewise Therapeutics (EWTX) is set to report first-quarter earnings, with analysts expecting wider losses of 49 cents per share and zero revenue, consistent with its pre-commercial status. Investors are focusing on clinical trial milestones for its muscle-disease therapies, including top-line data for sevasemten in late 2026 and Phase 2 results for EDG-7500 in cardiac hypertrophic cardiomyopathy in Q2. Despite a $4.09 billion market cap and no revenue, Wall Street maintains a "buy" rating, although trial delays or disappointing data pose significant risks.
Edgewise Therapeutics (NASDAQ: EWTX) posts Q1 2026 net loss of $49M
Edgewise Therapeutics reported a wider net loss of $49.0 million in Q1 2026, compared to $40.8 million in Q1 2025, due to increased R&D and G&A expenses as it advanced its clinical pipeline. Despite the loss, the company maintained a strong cash position of $499.6 million and highlighted positive long-term data for sevasemten in Becker muscular dystrophy, with pivotal data expected in Q4 2026, alongside upcoming readouts for its cardiovascular programs. The focus remains on pipeline progress with several key clinical milestones anticipated.
Why Edgewise Therapeutics (EWTX) Is Up 21.5% After Positive Trial, FDA Updates And Equity Grants
Edgewise Therapeutics (EWTX) shares rose 21.5% following positive drug trial results, FDA developments, and the granting of incentive stock options to new employees. The company's investment narrative is heavily tied to the success of its late-stage neuromuscular and cardiac programs, with clinical readouts serving as key short-term catalysts. Despite ongoing losses and zero revenue, management's strategic hires and pipeline underscore a focus on execution, though funding risk remains given current losses and a potential overvaluation.
Edgewise Therapeutics 1Q 2026: Net income $(49.0M), EPS $(0.46) — 10-Q Summary
Edgewise Therapeutics reported a net loss of $(49.0M) for the first quarter of 2026, an increase from $(40.8M) in the prior year, with diluted loss per share widening to $(0.46) from $(0.43). The company highlighted clinical advancements across several programs, increased R&D investment for later-stage trials, and expanded operational capacity. Management stated that current cash resources are expected to fund operations for the next 12 months.
Edgewise Therapeutics (NASDAQ: EWTX) reports Q1 2026 loss, $499.6M cash
Edgewise Therapeutics (NASDAQ: EWTX) reported a net loss of $49.0 million for Q1 2026, primarily due to significant investments in a late-stage clinical pipeline targeting severe muscle and cardiac diseases. Despite the loss, the company maintains a strong liquidity position with $499.6 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next 12 months. The company is actively advancing several clinical programs, including sevasemten, EDG-7500, and EDG-15400, while also navigating the complexities of regulatory approvals and market competition.
EDGEWISE THERAPEUTICS ($EWTX) Releases Q1 2026 Earnings
EDGEWISE THERAPEUTICS ($EWTX) reported its Q1 2026 earnings, posting a loss of -$0.46 per share, which beat analyst estimates. The company's revenue was $0, matching expectations. The article also details recent insider trading activity, with more sales than purchases, and significant hedge fund movements in Q4 2025, alongside analyst ratings and price targets for EWTX.
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications
Edgewise Therapeutics reported its first-quarter 2026 financial results and provided updates on its clinical programs. The company highlighted positive long-term data for sevasemten in Becker muscular dystrophy, showing sustained functional stabilization for up to 3.5 years. Additionally, Edgewise anticipates reporting 12-week data for EDG-7500 in hypertrophic cardiomyopathy in Q2 2026 and pivotal results for sevasemten in Becker muscular dystrophy in Q4 2026.
Edgewise Therapeutics earnings on deck as losses widen
Edgewise Therapeutics is set to report its first-quarter results, with analysts expecting a wider loss per share of 49 cents as the company advances its muscle-disease therapies. Despite no revenue generation and consistent quarterly losses, the biotech firm has a market capitalization of $4.09 billion, driven by upcoming clinical trial milestones for its experimental drugs sevasemten and EDG-7500. Investors are closely watching cash burn and the path to commercialization, as trial delays or disappointing data pose significant risks given the company's premium valuation.
Why Edgewise Therapeutics (EWTX) Is Up 21.5% After Positive Trial, FDA Updates And Equity Grants
Edgewise Therapeutics (EWTX) stock rose 21.5% following positive drug trial results and FDA-related updates, alongside the issuance of inducement stock options to new employees. The company's investment narrative is heavily tied to its late-stage clinical programs for neuromuscular and cardiac disorders, with current positive news reinforcing confidence in its catalyst-rich pipeline. However, the article notes the company's ongoing losses, zero revenue, and potential overvaluation, suggesting funding and execution risks remain.
Truist Securities Adjusts Price Target on Edgewise Therapeutics to $52 From $46, Maintains Buy Rating
Truist Securities has increased its price target for Edgewise Therapeutics (EWTX) from $46 to $52, while reiterating a "Buy" rating on the stock. This adjustment reflects an updated outlook from the firm regarding the biopharmaceutical company, which specializes in therapies for muscular dystrophies and cardiac conditions. The article also briefly mentions recent news about Edgewise Therapeutics, including other analyst rating changes and updates on its clinical trials and financial performance.
Edgewise Therapeutics (Nasdaq:EWTX) - Stock Analysis
Edgewise Therapeutics (EWTX) is a biopharmaceutical company focused on therapies for muscle disorders, with a market cap of US$4.0b. The company reported a Q1 2026 net loss of US$49.0 million but holds US$499.6 million in cash, funding ongoing late-stage clinical programs. Key pipeline developments include sevasemten for Becker muscular dystrophy, with Phase 3 results anticipated in Q4 2026, and cardiovascular candidates EDG-7500 and EDG-15400.
Edgewise Therapeutics CMO Donovan sells $2.09 million of stock
Edgewise Therapeutics CMO Joanne M. Donovan sold approximately $2.09 million worth of company common stock, executed under a Rule 10b5-1 trading plan. These sales occurred shortly after Donovan exercised stock options to acquire 50,000 shares. Despite these sales and an "overvalued" assessment by InvestingPro, analysts from Raymond James, Truist Securities, JPMorgan, and Evercore ISI have maintained or raised their price targets and ratings, citing promising clinical trial data and pipeline potential for the company.
50,000-share sale notice for EWTX (NASDAQ: EWTX)
A Form 144 filing indicates a proposed sale of 50,000 shares of Edgewise Therapeutics (EWTX) common stock following an option exercise dated May 5, 2026. The filing also details prior Rule 10b5-1 sales by the same individual, totaling 71,588 shares between March and May 2026, with specified cash proceeds for each transaction. This is a routine regulatory disclosure providing transparency on insider stock activity.
Edgewise Therapeutics CMO Donovan sells $2.09 million of stock
Joanne M. Donovan, CMO of Edgewise Therapeutics, sold approximately $2.09 million worth of company stock through a Rule 10b5-1 trading plan. These sales occurred after the company's stock saw a significant 90% gain over the past year, trading near its 52-week high. Concurrently, Ms. Donovan also exercised options to acquire 50,000 shares, reflecting ongoing activity amidst positive analyst outlooks and promising clinical trial data releases for the company.
Edgewise Therapeutics (EWTX) CMO sells 55,230 shares under 10b5-1 plan
Edgewise Therapeutics' CMO, Joanne M. Donovan, exercised stock options for 50,000 shares at $7.08 and subsequently sold a total of 55,230 shares at average prices of $31.2931 and $38.568. These transactions, which occurred on May 4 and 5, 2026, were conducted under a pre-established Rule 10b5-1 Plan from December 26, 2025. Following these sales, her direct holdings in Edgewise Therapeutics common stock are reduced to 4,367 shares.
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics?
Shares of Cytokinetics (CYTK) surged after positive late-stage trial results for its hypertrophic cardiomyopathy (HCM) treatment, Aficamten, which met both primary endpoints. Analysts, including Truist, raised price targets for CYTK, while also expressing bullish sentiment for Edgewise Therapeutics (EWTX), whose EDG-7500 drug for HCM is considered well-positioned. Despite CYTK's positive results, analysts suggest that EWTX's therapy may be even better suited, leading to significant stock gains for both companies.
Edgewise Therapeutics stock hits 52-week high at $39.96
Edgewise Therapeutics (EWTX) stock reached a new 52-week high of $39.96, driven by investor confidence and strong performance over the past year. The company has also reported positive results from its MESA open-label extension study for Becker muscular dystrophy, leading multiple analysts to reiterate "Buy" or "Overweight" ratings with increased price targets. However, InvestingPro analysis suggests the stock is currently trading above its Fair Value and is considered overvalued.
Edgewise Therapeutics Reports Inducement Grants As Permitted By The Nasdaq Listing Rules
Edgewise Therapeutics (EWTX) has reported inducement grants, as allowed by Nasdaq Listing Rules. This brief announcement was made through Refinitiv and published on TradingView News.
9 new Edgewise hires receive stock options for 266,000 shares
Edgewise Therapeutics announced it granted inducement stock options for a total of 266,000 shares to nine new non-executive employees on April 30, 2026. These options have an exercise price of $30.96 per share and vest over approximately four years, with an initial 25% vesting after one year. The grants were made under the company's 2024 Inducement Equity Incentive Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Edgewise Therapeutics, a biopharmaceutical company specializing in muscle diseases, announced the grant of inducement stock options to 9 new non-executive employees. These options, totaling 266,000 shares at $30.96 per share, vest over time and were issued under the company's 2024 Inducement Equity Incentive Plan, adhering to Nasdaq Listing Rule 5635(c)(4). This move aims to attract and retain key talent as the company continues developing novel therapeutics for muscular dystrophies and cardiac conditions.
Avoiding Lag: Real-Time Signals in (EWTX) Movement
This article provides an analysis of Edgewise Therapeutics Inc. (NASDAQ: EWTX), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strength, support, and resistance levels for EWTX.
Moody Aldrich Partners LLC Has $1.07 Million Holdings in Edgewise Therapeutics, Inc. $EWTX
Moody Aldrich Partners LLC significantly reduced its stake in Edgewise Therapeutics, Inc. by 48% in the fourth quarter, now holding 43,134 shares valued at $1.07 million. This comes as Edgewise Therapeutics shares are trading near a 52-week high, with a market capitalization of $3.27 billion and a "Moderate Buy" consensus rating from analysts with an average price target of $38.13. Additionally, a corporate insider recently sold a substantial number of shares, though insiders still collectively own 23.20% of the company.
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of "Moderate Buy" by Analysts
Nine analysts have given Edgewise Therapeutics (NASDAQ:EWTX) a consensus "Moderate Buy" rating, with an average target price of $38.13, despite some recent "sell" ratings. CMO Joanne M. Donovan recently sold a significant number of shares, while institutional investors like Peregrine Capital and Invesco have increased their holdings. The biopharma company, focused on rare diseases with its drug EWTX-101, recently missed EPS estimates but has seen its stock rise by 1.7%, opening at $30.96 with a market cap of $3.33 billion.
Edgewise Therapeutics, Inc. $EWTX Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH significantly increased its stake in Edgewise Therapeutics (NASDAQ:EWTX) by 104.8% in Q4, acquiring 271,385 shares valued at approximately $6.73 million. Analysts maintain a "Moderate Buy" rating with an average price target of $38.44, despite a recent EPS miss. Company CMO Joanne M. Donovan recently sold a substantial number of shares, while insiders collectively own 23.2% of the company.
Edgewise Therapeutics (NASDAQ: EWTX) holder Novo Holdings at 4.98%
Novo Holdings A/S has filed an amendment indicating its stake in Edgewise Therapeutics (EWTX) has fallen to 4.98%, below the 5% threshold requiring a Schedule 13D filing. This change is due to dilution rather than any sale or purchase of shares, and Novo Holdings confirms no transactions in EWTX shares have occurred in the past 60 days by them or associated entities. The filing clarifies that Novo Holdings beneficially owns 5,350,000 shares, with sole power to vote and dispose, and ceased to be a 5% beneficial owner on April 23, 2026.
Edgewise Therapeutics (EWTX) Valuation Check After Strong Multi Year Shareholder Returns
Edgewise Therapeutics (EWTX) has shown strong multi-year shareholder returns, with the stock trading around $31.58. Despite this performance, its Price-to-Book ratio of 6.5x indicates it is overvalued compared to the broader US pharmaceuticals industry average of 2.4x, though cheaper than its immediate peers averaging 22.5x. The company faces pressure points including significant losses and no current revenue, highlighting the sensitivity of its valuation to progress in drug development and commercialization.
RBC Capital Remains a Buy on Edgewise Therapeutics (EWTX)
RBC Capital has reiterated a Buy rating for Edgewise Therapeutics (EWTX) with a price target of $50.00, following an analyst's strong track record in the Healthcare sector. Despite a negative corporate insider sentiment due to increased insider selling, the analyst consensus remains a Strong Buy. The company reported an increased GAAP net loss in its latest quarter.
EWTX Price Today: Edgewise Therapeutics, Inc. Stock Price, Quote & Chart | MEXC
This article provides details on Edgewise Therapeutics, Inc. (EWTX) stock performance and company information. Currently trading at $31.58, EWTX has shown strong performance over the last year with a +101.40% price change. The company is a clinical-stage biopharmaceutical company focused on developing therapies for muscular dystrophies and cardiac conditions, with several product candidates in development.
[ARS] Edgewise Therapeutics, Inc. SEC Filing
This article announces an SEC filing of Form ARS by Edgewise Therapeutics, Inc. (EWTX) on April 23, 2026, at 4:10 PM. The filing's impact is categorized as low with a neutral sentiment. The article also provides an overview of EWTX's stock data, including its market cap, float, industry, and recent news and SEC filings.
Edgewise Therapeutics (EWTX) outlines 2026 director elections, pay and auditor vote
Edgewise Therapeutics has released details for its 2026 annual shareholder meeting on June 4, 2026, where stockholders will vote on the re-election of three Class II directors, the ratification of KPMG LLP as the independent auditor for fiscal year 2026, and an advisory vote on executive compensation. The proxy statement details the independence and staggered structure of the board, non-employee director compensation, and the company's governance policies, including an Insider Trading Policy and Compensation Recovery Policy. Executive compensation highlights for 2025 include base salary and bonus adjustments, with significant long-term incentive compensation through equity awards aligning executive interests with stockholder value.
Discipline and Rules-Based Execution in EWTX Response
This article provides an analysis of Edgewise Therapeutics Inc. (NASDAQ: EWTX), highlighting strong sentiment across all horizons and an exceptional 44.6:1 risk-reward short setup. It details AI-generated trading strategies for different risk profiles, including long, breakout, and risk hedging strategies, along with multi-timeframe signal analysis. The report also notes key support and resistance levels for near-term, mid-term, and long-term horizons, based on quantitative research.
Edgewise Therapeutics stock hits 52-week high at 34.03 USD
Edgewise Therapeutics (EWTX) stock reached a new 52-week high of $34.06, marking a 187% increase over the past year. The biotech firm, specializing in treatments for rare muscle disorders, has seen its market capitalization rise to $3.63 billion, driven by positive market sentiment and advancements in its product pipeline. Despite its current unprofitability, analysts maintain positive ratings and price targets, anticipating future catalysts.
Edgewise Therapeutics stock hits 52-week high at 34.03 USD By Investing.com
Edgewise Therapeutics Inc. (EWTX) stock reached a new 52-week high of $34.06, reflecting a 187% increase over the past year and a 123% return in the last six months. Despite its strong market performance, the company remains unprofitable with an EPS of -1.63 USD, and analysis suggests the stock may be overvalued. Analysts from Raymond James, Truist Securities, Evercore ISI, and JPMorgan have reiterated "Buy" or "Outperform" ratings with price targets up to $46, following positive data from the MESA study for its Becker muscular dystrophy treatment, sevasemten, and anticipation of upcoming EDG-7500 data in 2026.
Analysts Bullish on Edgewise Therapeutics Stock
Analysts are optimistic about Edgewise Therapeutics (NASDAQ:EWTX) due to its innovative drug candidate, EWTX-101, which targets rare kidney and neuromuscular diseases. A consensus price target of $38.44 has been set, with most analysts issuing 'Buy' or 'Strong Buy' ratings. The company's stock has risen over 30% year-to-date, showing strong commercial potential for its pipeline focused on unmet medical needs.
Behavioral Patterns of EWTX and Institutional Flows
This article analyzes the behavioral patterns and institutional flows of Edgewise Therapeutics Inc. (NASDAQ: EWTX), indicating a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional risk-reward short setup and provides three distinct AI-generated trading strategies with specific entry, target, and stop-loss zones for different risk profiles. The analysis includes multi-timeframe signal analysis with support and resistance levels.
Aberdeen Group plc Increases Position in Edgewise Therapeutics, Inc. $EWTX
Aberdeen Group plc significantly increased its stake in Edgewise Therapeutics (NASDAQ:EWTX) by 32.6% in Q4, acquiring over 200,000 additional shares. This move brings their total holdings to 821,940 shares, representing approximately 0.78% of the company. Despite some insider selling from a director and CMO, Edgewise Therapeutics maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $38.44.
Why Edgewise Therapeutics (EWTX) Is Up 8.1% After New Sevasemten BMD Data And Analyst Interest
Edgewise Therapeutics saw an 8.1% increase in its stock price after reporting positive long-term results from its MESA study for Becker muscular dystrophy treatment, sevasemten. This, coupled with growing analyst interest in its pipeline assets like EDG-7500, has driven attention to the company's clinical trajectory. However, the article notes that persistent losses and no clear profitability timeline remain concerns for investors.
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Recommendation of "Moderate Buy" by Analysts
Analysts have given Edgewise Therapeutics Inc. (NASDAQ:EWTX) a consensus "Moderate Buy" rating, with an average 12-month price target of $38.44. This comes despite recent insider selling by the CMO and a director, and the company missing its last quarterly EPS estimates. Edgewise Therapeutics is trading near its 52-week high, with a market capitalization of approximately $3.58 billion.
Edgewise Therapeutics (EWTX) Valuation After Positive Becker Muscular Dystrophy Extension Data
Edgewise Therapeutics (EWTX) is attracting attention due to positive long-term MESA extension data for sevasemten in Becker muscular dystrophy, leading to a significant rally in its share price. Despite its current high price-to-book ratio compared to the broader US Pharmaceuticals industry, the company's valuation is considered "about right" when compared to its pre-revenue biopharma peers, reflecting investor confidence in its drug pipeline. However, the company still faces clinical trial risks and ongoing net losses requiring future funding.
SG Americas Securities Boosts Stake in Edgewise Therapeutics
SG Americas Securities significantly increased its stake in Edgewise Therapeutics (NASDAQ: EWTX) by nearly 800% in the fourth quarter of the prior year, bringing its total holdings to 88,723 shares. This move suggests the institutional investor sees substantial potential in Edgewise Therapeutics, a clinical-stage biopharmaceutical company focused on rare disease treatments. The increased investment underscores the biotech firm's importance in the rare disease treatment landscape and its pipeline's future growth prospects.
SG Americas Securities LLC Buys 78,842 Shares of Edgewise Therapeutics, Inc. $EWTX
SG Americas Securities LLC significantly increased its stake in Edgewise Therapeutics, Inc. by 797.9%, now holding 88,723 shares valued at approximately $2.20 million. This move comes amidst notable insider selling by the company's CMO and director, collectively reducing insider ownership to 23.20%. Edgewise Therapeutics currently trades near its one-year high with a market cap of $3.58 billion and maintains a "Moderate Buy" consensus rating from analysts, with JPMorgan Chase & Co. recently raising its price target to $45.00.
Edgewise Therapeutics (EWTX) Valuation After Positive Becker Muscular Dystrophy Extension Data
Edgewise Therapeutics (EWTX) is gaining attention after releasing positive long-term extension data for sevasemten in Becker muscular dystrophy patients, showing stable function. Despite a significant rise in share price, the company's valuation is being re-examined in the context of its P/B ratio and comparison to industry peers. Investors are currently valuing its pipeline, clinical data, and management track record, given that Edgewise is a pre-revenue, loss-making biopharma company.
